2024-03-31-accounts

Registered number: 04509293 Charity numbers: 1094231 & SC039257 The British Allergy Foundation (A company limited by guarantee) Trustees. report and flnanclal statemants For the year ended 31 March 2024 ¢￿I56E01• 1711212024 COMPANIES HOUSE AOS

115

The 8rltlsh Allergy Foundatlon (A company Ilmited by guarantee) Contents Page Reference and admlnlstratlvo dolall8 of the Chorlty, Its Truste¢8 and advis•r8 Truslees. report 2-16 Independent audltors. report on the financial stalemenls 17-21 Consolidated slatemenl of financlal activities 22 Con8011daled balaTrce sheet 23-24 Charlty balance shaol 25-26 Consolldated statement of cash flows 27 Notes to the financial slatemenls 28-54

The British Allergy Foundation (A company limiled by guarantee) Reference and admlnlslralive delalls of the Charlty, Its Trustees and advlsérs For the year ended 31 Maich 2024 Trustees Mr P Frampton, Chair Mrs A Tharani, Vice Chair Mr R Daby Mr R Dudley-southern MBE (￿Signed 28 Seplember 2023) Dr B Hewill (resigned 28 September 2023) Dr G Stiefel Dr S Kayode Ms R Oldroyd Ms L Pritchard (resigned 26 September 2024) Ms K Sykes (appointed 17 June 2023, resigned 2 April 2024) Ms E Withers Ms S Devlin (appolnted 28 September 2023) Company reglstered number 04509293 Charlty reglstered numbers 1094231 and SC039257 Reg18t•red offlce London House Buslness Cenlre Thames Road Crayford Dartford England DA14SL Company secretary P Turnbull Chl&f executlve offlc•r S-miles Independent audllors Kreston Reeves LLP Chartered Accountants statutory Auditor 37 St Margaret's Street Cantert>ury Kent CT12TU Page 1

The British. Allergy Foundallon (A company limited by guarantee) Trustees, report For the year ended 31 March 2024 The Truslees present their annual report logether wilh the audited financial statements of the Charily for the 1 April 2023 to 31 March 2024. The Annual report serves the purposes of bolh a Trustees, report and a directors. report under company law. The Truslees confirm thal Ihe Annual report and financial slatemenls of the charilable company comply with the curfent statutory requirements, the requirements of the charilable company's governing document and the provisions of the Stalement of Recommended Practice (SORP) applicable to charilies preparing their accounts in accordance wilh the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS102) (effective 1 January 2019). Since the group and the Charity qualify as small under section 383 of the Companies Act 2006, Ihe Group strategic report required of medium and large companies under the Companies Act 2006 (Strategic Report and Directors, Report) Regulations 2013 has been omitted. The group and the Charity also Irade under the name Allergy UK. ObJe¢llves and acllvlllos a. Pollcles and objectlves The Charitable Objects for the charity'are.. 3.1 To raise public awareness around allergy and the causes of anaphylaxis. 3.2 To produce reliable information and education in the community for the managemenl and prevention of all allergic reactions, including anaphylaxis. 3.3 To provide support In the community lo all those affecled by allergy. covering all manifeslalions of allergy to reduce risk of serious allergic reaction (anaphylaxis). This support extends to bereaved families, 3.4 To promote research into the cause and care for all allergic conditions. including those Ihal cause anaphylaxis. in order to improve health and quality of lile for people living with allergy and associated diseases. 3.5 To increase the profile of and advocacy for all allergic conditions. including the seriousness of anaphylaxis, providing advice and representation to government, industry, and other organisations, and being a conduit for infom)ation and research for a range of expert and patient stakeholders. 3.6 To campaign for policy and legislative changes to improve the INes of 811 people living with allergy, including those who live with the fisk of anaphylaxis. In selling obleclives and planning for adivities, the Trustees have given due consideration lo general guidance published by the Charity Commission relating to public benefit, including the guidance 'Public beneflt.. running a charity (PB2)'. Achlevements and performance a. Maln achievements of the Charlty In 2023124 we continued to work towards Our Strategic objectives as set out in our Slrategy for Change 2020- 2025 plans. Page 2

The Britlsh Allergy FoundalSon IA company limlted by guaranteo) Trustees. report (eontinuedl For the year ended 31 March 2024 Achlevements and performance Icontlnued Research - Underslanding Allergy Patlent Charter for People Livlng wlth Allerglc Disease Research Is used to inform the services we provide and public affairs campaigns. We lobby on behalf ol the allergic community. and the slrategic approach of the charity. Oui real.world evidence suNey and focus groups in 2021 led to a collaboration between patients, carers, clinicians and Allergy UK and the development of Patient Charter (or People Living with Allergic Disease. The Chartels key focuses are.. A right to a quality standard of care.. for everyone living with allergy throughout the UK right lo accurate information and educalion.. Empowerment of patients wilh allergic conditions to understand and manage their candilion with support frorn informed heallhcaie professionals A right to equalrty in society.. Promotion of a belter awareness and understanding of aller9y 80 that people with allergic conditions are not discriminated against in any aspect of Iheir daily lives. -since the inception of the charter, our campaign has concentrated on advocating for the inclusion ol specialist allergy nuTses and dlelrtians within every Integfated Care Board {ICB). ICBS are nol lasked with commissioning allergy service$ at a local level and do nol encompass specialist services. In March 2023, Allergy UK submitled a Freedom of Infomalion request to all 42 ICB$. The findings from this request were regrellabty unsurprising, Indicating that allergy ser4ices do nol adequately address the genuine needs of Ihe population. Out of 42 NHS En9land ICBS approached, 32 piovided responses, while Ihe remining 10 did not reply. Among the 32 ICBS that responded. only 3 (representing 7•10 of all ICBS) possessed data regarding the number of palienl8 within their area who had been clinically diagnosed and coded with an allergy. Currently, there are only 8.539 patients whose conditions are documented at the ICB level during Ihe specified timeframe. The research has been instrumental in shaping meetings and Westminster Briefings with the Government. We continue our efforts to raise awareness about the crilical nature of allergies and the necessrty of improved allergy services. In the laller end of 2023. Allergy UK commissioned 8 lood allergy community survey for our food allergy phase of Ils Time campaign. IngTedienls Malter. Although Allergy UK have a signrficant amount of anecdotal evldence 8boul the challenges of living wilh a lood allergy from lack of transparent labelling, refusal of service at ieslauranls and heightened anxiety for those affected. We were missing robusl, qualilaliv8 data that can be used more effeclively to utilise and inform our planned initialives over Ihe coming years. This survey looked to understand the daily implications and restrictions faced by the food-allergic community to keep themselves safe., We are currently reviewing Ihe data lo understand how best lo use il to inform Our communily and the work'we do. Empowerlng - supportlng and Informlng through our Helpllne and resources There has been a notable rise ITr the demand for support services for individuals facing mental health challenges, including anxiety and depression. Our advisers offer immediate assistance and appropriate referrals lo either our internal specialist clinical team or external services as necessary. In the fiscal year 2023124, we assisted 7,000 indivlduals Ihrough our helpline, marking a 530/0 increase compared lo 2022123. Additionally, our Allergy Translation Card Service offers both plastic and PDF cards in 35 languages for those needing lo communicate Iheir allergies in a langua9e olher Ihan English. During 2023124, we processed 2,095 translalion Gards. In March of this year, we launched an enhanced online ordering system. allowing customers to request their cards at their nvenience. Preliminary leedback indicates Ihal this new melhod is well-received, with a significant number of orders being placed outside of regular business hours. We anticipale providing more comprehensive insights next year after a full year of service operation. This development is beneficial for both consumers and the charily, as it enhances service accessibilily and conliibules to increased revenue for the organisation. We exlend our gratitude to our Health Advisory team for their dedication In providing expert clinical support for calls received through our helpline. Pa9e 3

The Brilish Allergy Foundallon {A company limlted by guarantee) Truslees. report (continued) For the year ended 31 March 2024 Achlevements and perfomiance (cont6nued> Eczema Clinlc Allergy UK boasts an in-house clinical team dedicated to providing expert support for allergy-related issues. In our annual report from the previous year, we recognised the necessity of establishing an Eczema Senil￿. We are pleased to announce that a Nurse Led Eczema Clinic began its testing phase in September 2023. operating one day each week. From Seplember to March, the clinic assisted 16 children and their families dealing wilh persistent and challenging eczema. The sep4ice is conducted through personalised lelephone consultations, offering guidance and supporf lo help parents better comprehend and manage their child's atopic dermatitis. Following a review of the seniice'5 impact, we have decided to continue the clinic, with Ihe aim of securing funding ihrough grants or sponsorship. Dletltlan S•rvl¢• The service has been operational since 2015. assisting more than 1.700 children throughout this time. with 286 children receiving support in Ihe 2023124 period. It offers assistance to parents and caregivers of children with suspected f¢)od aller9ies, providing professional dietetic intervention while they await an appointment with Ihe NHS. We aspire for this seNice to remain sustainable through ongoing grants and sponsorship. as feedback from parents consistenlly highlights the npcessity of such support and the significant positive effecls il has on both them and their children. We get frequent positive feedback Irom parents using the 8eNice. This is one example, My free phone call wllh dielilian for my baby was exlremely helplull ltre been in conlacl wilh my GP around 8.limes. and Iheytre iiol helped, so gelling advice froin someone else was nicel They (helpline adviser) helped pul my mind 81 ease wilh lips for how to help my allergy baby wean and'what new foods to Iry Ihem wilh and when. My GP also received 8 lelter which hopefully will help lo speed lip my refeffal for 811ergy lesls. Id recommend lh6 seNice lo anyo1￿ who slniggles wilh lood allergies 8nd has nol golten help anywhere else. Th8nk youl Youth engagement Over the past year, the youlh engagemenl program has experienced signilicant grovAh and development." The Youth Engagement Group has convened on 12 occaslons, in addition lo 10 steering committee meekn'ngs and 10 discussions between the Chair, a young member of the group, and the lead represenlalive from Allergy UK. The typical attendance of young participants flucluales between 9 and 15 individuals. The youth group delved into various allergy-relaled topics, receiving guidance from our inthouse clinical team. In the upcoming year, ive plan to broaden our youth groups to include a younger demographic. Regrellably, funding for a youth engagemenl officer has concluded. We are aclively pursuing granls to secure addilion81 funding. In the interim, Ihe engagement program is being managed by another team member wilh expertlse in youth engagement. Allergy UK has engaged in an exciling Initiative in collaboration with Ihè Girl Guides London and Soulh East region (LASER) lo develop an allefgy awareness badge. We are delighted to announce that the Allergy Aware badge was officially launched in April 2024. This badge aims to empower Ihe younger generation to become more knowledgeable about allergies and lo asslst their peers who may be affected. The partnership with the Girl Guides adds significant value, as it includes a commitment to fundraising efforts for Allergy UK. Should the badge prove successful in 118 Inaugural year. we aspire lo e*Éend Ihis initiative lo addilional regions throughoul Ihe UK, Educating - Impffoving awareness, knowledge. and sk511s in allergy Our educational resources support patienls, caTer8, 8nd non-specialist healthcare professionals in developing knowledge ol allergic disease and in 2023124 we developed many excellenl additional resources to provide advice and informalion for people living with allergy. We launched a skin focused phase of our campaign called 'lt's Time. using digilal ads, social media and case studies. The campaign performed very well reaching three times as many useis compared to previous. campaigns. Page 4

The British Allergy Foundatlon (A company Ilmlted by guarantee) Trustees. report (conlinued) For the year ended 31 March 2024 Achlevements and performance (continued) We served as a collaborative partner for Nalional Eczema Week, actively disseminaling infonnation via our social media posts. Our specialist allergy nurse provided valuable insighls through a Facebook post featuring three essenlial tips for individuals caring for atopic eczema skin. Additionally, a live Q&A Session was conducted to commemorate World Eczema Day. Allergy UK successfully conducted two Allergy Awareness weeks. In April. we introduced a new Parenl Palhways Hub on our website. which achieved the highest level of positive engagemenl compared to any other resource launched on social media. Our second awareness week in October 2023 concenlraled on indoor allergies, utilising a var￿tY of social media posts to provide valuable information on this topic. As 2023 drew to a close, we initiated the #lngredient8lAatter campaign, a creative initiative within the food segment of Ihe It's Time Campaign, This social media campaign, characterized by organic outreach, airned lo strengthen connections with the food allergic community. The reach ol #lngredienlsmaller surpassed that of the previous Food Campaign, despite both campaigns being active on social channels for the same duration as the prior year. This initiative has also positively impacted our Instagram follower count, reflecting a year-on-year grovAh of 25(A+ . We have created various resources aimed at individuals affected by allergies. These include a patient experience narrative regarding immunotherapy. a video showcasing the experiences of a child with House Dust Mile Allergy from both the Ghild's and the parenl's. viewpoints, as well as an infoimalional leaflet on cow's milk allergy, Addilionally, our website has been enhanced lo feature a dedicated section for parents of young individuals. providing them with access lo tfusiworthy resources10 assist in their allergy management. ln recent monlhs. Allergy UK has engaged in a partnership with the Helen Bly1he Foundation lo establish Schools Allergy Education Standards aimed al enhancing awareness and care foi children with allergies in educational sellings. This initiative stems Irom a Freedom of Information request directed at schools In England, inquiring about their managemenl ol allergies.. The findings from the Ready lo React Report indicated significant variability in trainin9, With over 400h of teachers expressing Ihat Ihey dld not feel adequalety prepared lo handle a child's allergy. In light of Ihese resulls, Allewgy UK, in collaboralion with other stakeholdersi has been working on developing Alleigy Standards lor schools. The Departmenl lor Education has communi¢aled its support for this iniliative and has expressed a willingness lo Collaborate with parlners on the subsequent steps. This effort will extend into the 2024125 period. We have continued our efforts to educate heatthcare professionals (HCPS) Ihiough our Masterclasses. In 2023, we conducted Ihree Masterclasses focused on food allergy. eczema. and the weanin9 process relaled to food allergies. These Maslerclasses have seen strong allendance. The online training allracted a.tolal of 987 participants on the day of the evenl, with an additional 611 accessing the training after the Iwe session. Over 97Vk of participants raled the training as either excellent or good. Furthermore, we have supplied HCPS with valuable resources. including an eczema e-booklet designed lo assist in accurate diagnosis, as well as a podcast Ihat delves Into Paediatric Aslhma and Ihe application of cOrt￿OSter01d$, In April 2023 we refreshed our HCP'S publication. The new publication is a 'bite-size' approach to information. We had anticipated the launch of our own catering program in 2023. This program is designed to address the identified gaps and assist catering slalf in enhancing Iheir confidence when seniing individuals with allergies. However, due to limiiations in staff resources. the launch has been postponed. We expect to introduce the program in the upcoming months. Page 5

The Brltlsh Allergy Foundatlon (A company limited by guarantee) Trustees, report {¢ontinuedl For Ihe year ended 31 March 2024 Achlevemenls and perfoimance {contlnu•d) Influenclng - connectlng wilh key stakeholders The Patient Charter Digital Hub was inaugurated in 2023, featuring the establishment of a pledge wall and the creation of a government pelition aimed at prompling governmental action. This initiative was bolstered by a public relations campaign thal garnered support from an Allergy UK advocale and facilitated media coverage across television and radio platforms. During the 2023-2024 period, we actively engaged with parliamentarians to enhance awareness regarding allergies and to persisl in our calls lo action slemming from the Patienl Charter introduced the previous year. In May 2023, vie participa.ted in a Westminstei Hall debale concerning a national lead for allergy and food labeling on menus. while also striving to encourage more Members of Parllament and Peers to assume Ihe role of Allergy Champions, ol which we currently have twelve. In March 2024, we organized a drop-in event at Westminster for MPS and Peels to unveil our election manifesto. This manifesto ser4es as the cornerstone for our calls lo aclion for the 2024-2025 period. complementing our ongoing campaign message. "Il's time to lake allergy seriously,., by engaging wilh key. influenceis and stakeholders to raise awareness about living with a chronic condition. The political landscape for 2025-2026 will piesent new chaI￿nge5 and opportunities wrth the advent of a new govemment. Allergy UK plays 8 Plvotal role as a core member of the National Allergy Strategy Group (NASG), lor which we also serve as the secretarial. Our primary objeclive wllhin the NASG is lo formulate a National Allergy Strategy, and we are proud to actively conlribule lo Ihis inilialive. which is set to be a live document by autumn 2025. Over the past year, the NASG has formed its Expert Advisory Group to 8SSlSt in the development ol the National Allergy Strategy and to guide policy formulation. The All-Party Parliamentary Group (APPG) eonvened.for its Annual General Meeling, during which ils members demonslraled their invaluable support for our efforts to enhance.awareness of allergies. We extend our gratilude to all APPG members and lo Ihe Chair. John Cruddus, for his steadfast commitment to our inilialives. As the Chair has now retired and stepped down, our locus for 2024125 will be lo seek a new Chair and addilional members for the APPG, ensuring that we rnainl8in a nelwork ol peers and parliamentarian$ for the future. Allergy UK also. plays a key inlluenclng iole at a UK level with involvement in,. the National Allergy Strategy Group, Ihe steeling group of the Children and Young People's Allergy Nelwork in Scotland (CYANS) the Patient and Public voice partner for NHS England's Specialised Commissioning Clinical Refefence Group for Immunology and Allergy Services represenls palienl perspeclives when asked by the. Medicines and Healthcare products Regulalory Agency IMHRA) and the National Instilule ol Clinical Excellence (NICE) a member ol the Royal College of Physicians. Improving Quality in Allergy SeNices (IQAS) accfeditation steerin9 group is a palienl represenlalive in many of the Brilish Sociely Allergy and Clinical Immunology (BSACI) activitie5 has regular meetings with the Food Standards Agency (FSA) and is a contaci for Ihe Food Standards Scolland (FSS) Allergy UK exerts ils inlluence al both European and global levels through partnerships with various peer organisalions. We work in conjunction wrth the European Federation of Allergy and Ain14ays Diseases, the European Academy of Clinical Immunology, and the Global Allergy and Asthma Patienl Platform. During the 2023124 period, our participalion has encompassed. attending steering groups focused on skin and food allergies, developing resources applicable across Europe. and iepresenling the UK to promote best practice. Page 6

The British Allergy Foundatlon (A company Ilmited by guarantee) . Trustees. report Icontinued For the year ended 31 March 2024 Achievements and performance (continued b. Fundralslng activities and Income generatlon Allergy UK is regislered with and has paid the Levy required by Ihe Fundraising Regulator. The Charity is a member of Ihe Instilule of Fundraising and complies with all required regulations, including ensuring all procedures comply with General Data Proleclion Regulations, thereby protecting the data of all who contact Ihe Charity. We are pleased to advise that we have not received any complaints relating lo lundraising during this year. A primary objective of our oiganisation is lo enhance our capacity for income generation lo ensure the long-term sustainability of the Charrty. This will necessrtate the developmenl ol a variety of income sources. including unrestricted lunds and 9rants.lhat will support our essential services. Below. we outline our existing income 8treams. The current environment for charities 8lrivbng to meet Iheir income goals remains challenging. as numerous Trusts and foundations are conslrained in their ability to provide funding, particularly in light of the Sncreasing number of charities seeking financial support. However, we have received indications that 2024 may herald a shift, with a rise in available gfant opportunities. Coporate Partner and grants Cornmunily fundraising and individual conlributions Trusls and grants Income generaled Ihrough the charilvs tradin9 subsidiary, Allergy Research Limited We would like to express our Ihanks to all the companies that ¢onllnued to support Allergy UK to meet It8 service delivery objectives. This support is essential for the suslainability of the charily be il through corporale sponsorships through our trading Subsidiary or our corporate granls. In 2023124 we had 13 eslablish corporate partners which has supported the delivery of key services, such as our Dietitian Service, Maslerclasses. an array of resources and national and world ¢ampaigns such as Worfd Eczema day and World eczema week. For this, we wish to thank Abbvie. Polti, Nutricia, Global Skin, Haymax. Novarlis, Qlsson, Pfizer. Sanofi, Vialiis. +Ecohydra, Thoma3 and Leo Pharma, Communlty Fundralslng The Hope Hoot is a musical evenvhootenanny that was led by John, Tamsin, and Jack Schwab held on behalf of Allergy UK and anolhew allergy chaTily. The primary purpose of the evenl was to raise awareness about allergies and the much-needed funds for charity. The evenl was a success. and we are scheduled to repeat the event in 2025. Our Christmas campaign for 2023, My Llfe, your Hands focused on a young person who almost passed away after being served the wrong dish whilst dining out with friends. The key objective of the campaign was to raise awareness of Ihe seriousness of allergy, highlighting the need for changes in Iraining and education for the hospitality sector. The My Lile, Your Hands Campaign was also Ihe launch pad for sharing the great news that Allergy UK are working in partnership with Girlguiding. The project used the campaign as launch pad to promote the introdudion of an allergy badge from April with 44.000 Leaders. Guides, Rangers. Brownies and Rainbows from London and Southern England in Ihe coming year. We are working towards a national roll out program in 2025. As well as raising awareness among children, young people and their families the collaboralion with the girl guides will help raise funds to help Allergy UK meet ils objectives. For our My Lile, Your Hands. Chrislmas event we raised inwme by 520A Compared to the previous year. Event attendance at the venue went up by 63•/0 and online atlendance by 2330/0. We were also fortunale to receive £5780 worlh of gift-in kind and pro-bono support. We would like lo thank Tesco. Asda, Genius Foods. B&Q. and our celebrities Ihat supported the event. Page 7

The Brltlsh Allergy Foundation IA company Ilmited by guarantee) Trustees. report (continued> For the year ended 31 March 2024 Achievements and perfomiance Icontinued) London Knightz continues lo offer their ongoing support to the cause and have held a sponsored walk in memory of Ruben. in which Allergy UK received £1,598. Allergy UK would like to extend our most sincere and heartfelt thanks lo the Bousquel family, The London Knightz and all Ihose who have so generously supported us over the past year. Allergy UK is extremely 4Jrateful to all of our supporters and those who have donated through fundraising. donating to appeals, legacies and other ways, as despite the continued difficulties from Ihe economic impact our supporters continue to give . We achieved a 27010 increase compared lo the previous year. We are finding Ihat our donations have increasingly become 'one-off' donations rather than regular giving. We would assume that people are slill not able lo give regularly bul will give when Ihey can financially afford to. Trust Fundral8lng The year 2023 has proven to be a difficult period for Irust income, and we were unable to achieve our largels. Nevertheless, our bid writer has persistently cultivated essential relationships with funders and has enhanced the qualily of our bid submissions, leading to some emerging successes. We have observed that the limeline for 9ranl decisions is longer than anticipated, bul we remain oplimistic for impiovements in 2024125. We extend our gralilude to Global Skin for their contribution of $2,407 CAD. Nutricia for £1.008, Kiln Famity Trust lor £500, Michael Cornish Charitable Trust for £1,000. Coop for £1.598, Novartis for £23,177, Garfield Weston £12,500 and Abbvie for £408 for Iheir ongoing support through granls Ihat lacilitale our work, Endorsemenls and Llcenslng Our trading subsidiary Allergy Research Limiled provides endorsemenls lor products which may provide support lor the symptoms experienced by people living with allergy. The company donates all profits to Allergy UK each year enabling the charily to ulilize Ihese unrestricted funds for operational and other costs. The income raised from endorsemenls and licensing remains consistent and is the core income for the charity. However this still is of the backdrop of a challenging economic climate. ARL have experienced a slower response tirne for them to commit lo one of our endorsement programmes. However interesl has remined high as such, as a key area to generate income for the charity additional resource has been placed wilhin the team to support the opportunilies to 9row the income in this area. All donated income from the trading subsidiary directly finances the charllys expenditure on operational activities and stafftn9 resources. Operational expenditure provides a helpline: the funding of a communications team to promole awareness of allergic diseases,. the employment of Ihree allergy nurses and a dielilian to support the helpline and provide subject matter expertise on allergy and immunology: a team supporting the trading activities and involvement with other organisalions wilh the similar focus on areas of allergic disease. All surpluses will be used to finance future charitable expenditure, either for ongoing activities. or one￿ff projecls. The tradlng subsidiary provides the Charity's principal funding source and continued to perform well desptte the difficult global economic conditions. Both its major aclivilies (operation of endorsement programmes and WOTking with corporate partners) exceeded expectations for the year, the budget for which had remained conservative %then considering the economic forecasts. Our tradin9 subsidiary activities are all aimed lo be of benelit towards achieving the Charitvs aims lo provide support lor Ihose living with allergy and raise awareness of allergic disease. Cash flow has been closety monilored Ihioughoul the year and all oulflows are planned and well within the Charily's resources. We have recently ieviewed where we hold our ieserves to ensure Ihey are accessible if required and gain the best return rate. The aclivrties carried out by the Charity's subsidiary, Allergy Research Limited, require higher costs compared to charity which only seeks public donalions. The endorsement scheme independently lesls applicants, producis using specialist laboralories al commensurale fees. Allergy Research Limited activities involve delivering projects, which are supported by sponsorship from our corporate partners. These projects are aimed at increasing public and healthcare professional knowledge and awareness of allergy issues. Page 8

The Brllish Allergy Foundation IA company limited by guarantee) Trustees. report {contlnuedl For the year ended 31 March 2024 Achlevements and perfomiance (contlnuedl The endorsement schemes and projects incur costs to enable the achievement of outcomes and many of them are now delivered through digital solutions lor which the Charity ulilises third party providers. These costs are covered using donated contributions from our corporate partneis and any surplus funds desi9naled for this purpose. The majowity of the Charitvs income is generated, via the subsidiary, by these two means. Financial review . Golng concern After making appropriate enquirie8, the Trustees have a reasonable 6xpeclation that the Charity has adequate resources to conlinue in operational existence foi the foreseeable futuie. For this reason. they continue to adopt the going concern basis in preparing the financial statements. Further details re9arding Ihe adoplion of the goin9 concern basis can be found in the accounting policies. b. ReseNes pollcy The Board of Trustees reviewed the reserves policy in accordance with the charitls strategic planning, operational decisions, budgeting and risk managemenl processes. At every Board meeling. the Trustees can see the movemenl in reserves and. therefore, are aware ol the level of rpserves held by the charity. In addilion. the reserves position is usually formally reviewed Iwi¢e a year in February and September. Financial risk management for the group includes ensuring that there is sufficient Contingency reserve to enable the group to respond lo an unloreseen event or emergency. The Truslees provide the CEO with the authority to make financial decisions relating to operational need, providing there are three to four months contingency reserves available. This is revisited every 6 months lo er)sure good financi81 practice.11 is Allergy UK'S policy that any financial decision that would resull in reducing the conlingency reseNes to under four months of the charitvs operational costs would have lo be escalated to the Board of Trustees for a decision. The charity receives a steady Income stream from its trading subsidiary. and it is consldered highly unllkely thal this would cease immediately. It is assurned that, lo sel the reserves level, income must be set at a level equal lo or exceeds expenses. There could, however, be a steady or sudden reduction in income arising from evenls outside of Allergy UK'S control and sufficient reserves should therefore be held to cover a stressed drop in income over a period ol six months. This would give managemenl time lo reduce headcounvcosts to malch the lower levels of income. The averaoe monthly income for the group in 2023124 was £116,692 and is currently £94,548 {Sept 2024) excludin9 inter group charges. The average operational costs (BAF overheads) were £101,188 and are currenlly £88.812 (Sept 2024). The balance on Ihe contingency reserve al 31 March 2024 was £466.220 so currently we are comfortably wilhin those margins. The contingency reserve must be held on deposit accounts at a mix of terms and malurity dates, but nol exceeding 12 months, lo enable the lunds to be accessed when required. The Trustees expect management to maintain a reserve cushion at least equal to the Ihree-monlh minimum and must be notified immediately when this drops below the four months provision level. The designated reserves on Ihe balance sheet continue lo differentiate free funds from those invested in fixed assets or committed lo other specific projecls. However, designated reserves represent free reserves allocated for a specific use by the Board and can be reallocated at their discretion. This differenliales them from restricled 'reserves that have been received for a specific purpose and can only be used to delivef that objeclive. Over the coming year management and the board will be revisiting our ReseNes Policy and ensuring Ihat we have appropriately considered any ongoinglupcoming projects and our working capital requirements to provide a more detailed approach to defining our Reserves Policy and minimum level of general funds. This will provide us wilh a clear basis lo communicate how we plan to utilise any surplus or to make up any shortfall. Page 9

The British Allergy Foundatlon IA company limited by guarantee) Trustees, report Icontlnued) For the year ended 31 March 2024 ¢. Flnanclal statements The financial.statements for the year end for 2023124 show an income of £1.400.303 and expenditure of £1.404,697, decreasing resenies by £4,394. The charitrfs income was severely below budget mainly due to recorded Granls'being below Budget by £173.343. This was offset to some degree by better-than-expected setllemenl monies from our fomier Planwell House landlord with a total of £1.13,688 being received. On a posillvg nole. co$t$ were well controlled during the year and overheads were £130.632 less than budgeled. Salary savings of £84,836, mainly attributable lo vacant posts. were Ihe largest element of this. The trading subsidiary, Allergy Research Limited {ARL). profit al year end was £654.625. Both Testing and Corporale Partner income w.ere seriousty below Budget. This was mainly offset by above than expected renewal income. d. Prlnclpal rlsks and uncertainties A strategic risk register is consislentty updaled and presented at each board meeting of the charity and its trading subsidiary, with more Irequenl updates as necessary. detailing planned mitigation strategies and the status of all identilied risks. It has been recognised Ihal Allergy UK has'the potenlial to enhance its risk recording practices. Therefore, in 2024, we will evaluate the existing recording methods and implement improvements after the assessment. Economlc cllmale and cost of Ilvlng The economic crisis persisted into 2023124. impacting all sectors. including charitable organisalions. Reports . indicate that many funders issued fewer funds in 2023 compared lo previous years. despile an increase in Ihe number ol charities seeking financial support. According lo information from the Institute of Fundraisin9 and various funders, this silualion is expected to improve by lale 2024. Despite the challenging e¢onomlc environment. our regular donations have remained stable, along Wrth other fundraising revenues meeling budgetary expectations. Amidst income challenges, 2023124 also witnessed a continued rise in seNice costs, increased salaries aligned with market benchmarks, and expenses associaled wilh Ihe office relocation. In Ihe 2022123 period, we noted a shift in the nature ol contracts secured by ARL, a trend Ihat has persisted into 2023. Our ARL clients have shown a reluctance lo explore new Pfoducls, preferring to maintain their existing offerings. Additionally, many of our corporate partners underwent significant organisalional changes throughout 2023, which adversely affected Allergy UK'S ability to secure subslanlial corporate funding. However, early 2024 has broughl a positive shift, with corporalions beginning to establish favorable relationships and demonstratin9 willingness lo support Allergy UK:s services. Finance ai)d Aiidil In 2022, we highli9hted the difficulty in locating a suitable Finance Business Manager wrth the necessary qualifications following the departure of the previous individual. The recruitment process exlended nearly a yeai, during which we engaged an external accountancy fim) to oversee the financial accounts. Consequently, significant portion of the financial responsibilities was assigned to the CEO and Operations Director. Upon, successfully filling the position in November 2022, 2023 was designated for the integration of the newly established Xero accounting system and for Ihe new Finance Business Manager to familiarise themselves with the financial framework of Allergy UK. Throughout the year. we also conducted a review and update of the financial procedures, developed a slaff finance procedure. and provided training to the staff. The accountancy firm Oculus continues to assist Allergy UK with payroll processing. Additionally, we have retained Kreslon Reeves as our auditors for another year, as approved by the Board of Trustees. Page 10

The Brltlsh Allergy Foundatlon (A company Ilmlted by guarantee) Trustees. report (continued) For the year ended 31 March 2024 Recrultment Challenges The posl-pandemic era has presented signilicant challenges. During the COVID-19 crisis, the team experienced reductions due to redundancies and some staff members opting not lo relurn. leading to recruitment difficulties as we aim to iebuild the team in 2023. Throughout this year, we have seen some employees depart, and the search for suitable replacements has proven lo be arduous. In July 2023, the CEO resigned, and il was not until March 2024 Ihal Ihe position was permanenuy filled, during which lime an inlerim appointment was made. Several positions remain unfilled. and work has been adjusted accordingly. This situation arises from the cessalion of funding with no alternative income sources for certain roles. as well as structural changes that have rendered some posilions unnecessary. The transilion back to the oflice following COVID-19 has been relatlvely seamless. However, our current model. which entails three days in Ihe office and two days of remote work, poses challenges in attracting new staff. Many candidates express a preference for a grealer number of remole workdays. This is an aspect that the Charity conlinually evaluates. Presently, Allergy UK has determined that the existing hybrid model is effective for Ihe organisalion, bul this will be reassessed annually as we monitor trends in the UK and identify prevailing practices. To foster a collaborative team environment, we organised a staff day in December and introduced Staff Awards for the first time. The feedback from employees was overwhelmingly positive, highlighting the appreciation for recognition. We plan to hold another staff day in the summer of 2024. Additionally, we have engaged with staff to identify potential benefits they would find valuable. Numerous suggestions were made, many ol which have been approved, including Life Assurance coverage. access to a benefits platform, regular team gatherings, and the continuation of hybrid working arrangements. We will per8isI in reachlng out to staff, enc¢)uraging further ideas to enhance employee welfare and work-life balance. Lease and Office Move In July 2023, Allergy UK transitioned lo a new location, a decision prompted not by preference bul by our landlord's request for us to relinquish our lease over five years ahead ol schedule. due lo Iheir inlention to repurpose the building. Such a significant relocation can often lead lo disruptions,. however, l am pleased to report Ihal Ihe process was executed smoothly, thanks to the efforts of the Allergy UK team. They have adapted well to the new environment, which adequately fulfills all necessary requirements. Furthermore, we weceive excellenl support from the landlord. who ensures Ihat the building iemains suitable for our needs.and promptty addresses any inquiries we may have. Succession Planning for a new CEO In 2022, our CEO informed Ihe Twstees and Directors of their intenlion lo resign after eight years in Ihe p051tion, citing health and personal reasons. They provided an extended notice period, with a departure dale set for 31 St July , 2023. allowing Ihe charity and its trading substdiary ample lime lo formulate a succession plan. The Operations Director assumed the role of interim CEO during the recruitment process for a new CEO, which began in the first quarter of the financial year and inilially yielded a successful appointment. Regrettably. the selected candidate withdrew in Seplember 2023, leading lo 8 new recruitment efforl that commenced in October 2023 bul did not succeed. At this juncture, the Interim CEO chose lo apply for the permanent position and was appointed in March 2024. Since taking on this role, the CEO has concentrated on advancing the organisational objectives and crafting Ihe slrategic plan for 2025-2030, ensuring oplimal support and services for Ihe allergic community in the fulure. Page11

The Brltlsh Allergy Foundatlon {A company limited by guarantee) Trustees. report {contlnued). For Ihe year ended 31 March 2024 Sustalned Income generatlon The primary financial risks encountered by the Charity are associated with the perfoimance of ils trading subsidiary, which is essential for generaling the anlicipaled profit levels. The Charity heavily depends on donations from this subsidiary to fund a significant portion of its charitable expenses. Addilionally, there are risks related to diminished donations, challenges in obtaining grant funding, and a potential decline in engagement from corporale partners wilh our initialives. Our forecasts for the next three to five years underscore the necessity for enhanced income streams to ensure the charl1￿3 stabilily and lo prevent the need for signilicant staff reslrucluring, In 2023. our tradin9 Subsidiary formulated a business execution plan aimed at income generation. To lacililale this plan. additional iesources within ARL were deemed necessary, and this posrtion was successfully filled al the start of the 2024125 financial year. It is anticipated that the new staff will help generate numerous leads. expand our customer base, and ullimalely increase revenue. Nevertheless. Ihe ongoing difficulties in securing income through trust5 and 9ranls. coupled with the need for stringent monit¢Ning of the Charitls expenditures, remain pressing concerns. Financial projections indicate that the Charily should be able lo cover its operating costs in Ihe coming years: however. Ihis area continues lo pose challenges, particularly if Ihe Charily aims lo fulfill its futur8 slralegic goals. Investing in the diversilicalion ol the Charitls income sources is expected lo miligale the risks associated with any single stieam being negatively impacted. However, thls effort occurs within a contexi of resource constraints faced by many organisations In the third sector, These financial risks are monitored closety by the Chief Executive and Finance Business Manager on a daily basis, and Ihe Board are provided with regular financial updates and foreca$ls lo enable them lo assess the ,Charills finantial position. This is a proper ￿lleCtIOn of the use of designaled lunds and Ihe payment of liabililies included on the balance sheel al 31 March 2024, The cash resources have been place(l on deposlls ranging from inslanl access lo 12. months fixed. term, in a manner Ihal provides for the funds lo be available should Ihey be required. In Ihls way we seek to maximise the interest earned Irom prudent inveslmenls while maintaining the accessibility of these resources. Structure. govemance and management a. Constltullon The organisalion is a charitable company limited by guarantee, in¢orpor8led in August 2002 having been fi'rst registered as an unincorporated charity in 1991. The company was established under 8 Memorandum of Association which slates the objects and powers of Ihe chaiilable company and is governed under ils Articles of Association. In addrtion to the Memorandum and Articles of Association the charily also operates under the Code of Good Governance approved by the National Council of Voluntary Organisalions and the Charity Commission. b. Melhods of appolntment or elèctlon of Trustees A maximum of 12 Trustees can be appointed and there are currently 9 on the Board as of March 2024. The Tiuslees meel at least four times a year al board meetings, with an Annual General Meetin9 was held in September. The Board of Tfuslees is responsible for Ihe strategic direction of the Charity and its policy. The Chief Executive (CEO), and appropriate members of the Executive team, attend the Board meetings as required bul have no voling rights. The directors of the company are also Ihe charity Trustees for the purposes of charity law and serve for a period of three years but rnay be reolecled for further periods of three years, up to a 10-year period. Our Trustee Katherine Sykes stepped down in March after a short teirn on the Board. Roy Dudley- Soulliern MBE, Brian . Hewitt also slepped down as their lerin came to an end. The Board would like to say a huge Ih8nk- you lo Katherine, Roy and Brian for their commitment and conlribulion over this term. Page 12

The British Alleigy Foundatlon (A company Ilmlted by guarantee) Trustees. report Iconllnued> For the year ended 31 March 2024 Struclure. governance and management (continued). The Truslees have the power to appoint any person to be a Trustee who may have a required skillset or expertise. By the nature of the work that the charity carries out. medical and business knowledge. is required on the Board of Trustees, and Ihis is well represented on the present board Trustees regularly ieview Ihe skills within the Board agalnst a desired list of skills, and this inlorms recruitment ol Trustees. In a recent skills check the Board have recognised that Ihe board would benefit fiom addilional trustees wilh skills in fundraising and markeling, In the coming 12 months, this will be addressed to try and secure this particular skill sel. The skills and expertise of the Trustees are used appropriately to steer the charity and lo support the CEO as and when required. We have been privileged to have such new expertise on the Board of Truslees, and during 2023124 recruilment is continuing. c. Organlsatlonal slruclure and declslon-maklng pollcles Allergy UK is led by a Chief Execulive Officer (CEO) who collaborates with the Board lo achieve the oiganisation's strategic goals. The CEO possesses delegated authority over the Charity's resources and oversees its daily operations: Following Carla Jones's resignation as CEO on 3111 July , 2023, Simone Miles assumed Ihe role of Interim CEO. having previously served as the Operations Direclor al Allergy UK. This interim position was maintained until Ihe recrLiilmenl process for a new CEO was linalised. During this period. the Head of Fundraising look on the responsibilities of Interim Operations Director. In March 2024, Simone Miles was officially appointed as CEO, and Jon Rodriguez was named Operations Director in May 2024. The Executive team, which comprises the Operations Director, Finance Business Manager, and Head of Clinical, offers specialised knowledge and assists the CEO in managing the charity's operations and ils Irading subsidiary. Since the Senior HR Officer's departure in August 2023, the Operations Direclor has also taken on responsibililies for HR and Facilities, opting not lo fill this posilion bul inslead lo manage these lunclions Ihrough outsourced services. The Executive leam supe￿iseS the Operational Managemenl team. which is tasked with executing service area activilies aimed al fulfilling our objectives in clinical services, communications, endorsemenls. fundraising, and helpline siipport. Additionally, leam members wilh expertise in projecl and data management aid Ihe charity in coordinating projects funded by grants and sponsorships, as well as in developing our customer relationship management syslem and dala management slralegies. d. Pollcles adopted for the Inductlon and Iralnlng of Trustees New Trustees are provided wilh a recruilmenl pack which provides detailed information on th& work of Ihe Charity. the Meinorandum and Articles ol Association. the Charity Good Governance Code, which sels Ihe principles and recommended practice for good governance, Ifustee job description and iesponsibilities and the last published accounts. An induction period is arcanged for new Trustees to familiarise themselves with the charity's work. They are welcome to our offices as well as on-line engagemenl with the team. In ?023 all trustees were invited to allend the December staff day and slafl awards and the slaff day in the summer of 2024. In the nexl 12 months we will be reviewing the Trustee induction lo ensure that il meets the requirements to on- board trustees efleclively. e. Pay policy for key management personnel The Trustees consider the Board of Trustees and the Chief Executive as key management personnel of the Charily. No remuneralion was paid lo the Trustees in the year excepl for relevant expenses. The pay ol Ihe Charily's Chief Executive is reviewed annually by Ihe Board ol Truslees and benchniarked with charities of siniilar size. Tlie Board acknowledged that the Chief Executive's pay in line with benchmark position and awarded an increase lo reflect this. Page 13

The Brllish Allergy Foundation (A company limiled by guarantee) Truslees, report (continued For the year ended 31 March 2024 Structure, governance and management (continued) f. Salary remunerallon for slaff All salaries are benchmarked and reviewed each year. In May 2023 the Truslees received a proposal from the Execulive team which was discussed and in June 2023 approved a pay increase of 30/4 for employees, back dated to April 1st 2023, with some adjuslmenls depending on length of service under one year. There were also two posts which received increased salaries due to benchmatking and performance. g. Allergy UK staff training . All slafl complete mandatory Iraining lor compliance wilh safeguarding and health and safely legislation: In addilion, our clinical team deliver in-house Ifaining for all staff on allergic disease, lo lake all staff through a journey of underslanding on the breadlh of allergy, what il is and how Ihe immune syslem's immunoglobulin Eis inlluencing allergic reactions, This in-house training covers atopic eczema, allergic rhinitis, allergic aslhma, food aller9y, eye allergy and anaphylaxis and other additional education identified. In 2023 all staff completed Ihe mandatory on-line training, which included Health and Safely. Fire Safely Awareness, Equalily, Diversity & Inclusion and Cyber-security, The Leadership Team also complete Management Iraining. Individual slaff also have an anniial appraisal, with regular one-lo-ones wilh Iheir lin8 mana9ers and idenlified training need5 included in personal development plans lo ensure the charity arid its trading sub'sidiary are supported by skilled and experienced learn members. h, Health Advlsory Board Allergy UK has eslablished a longstanding Health Advisory Board comprising over 20 members. In March 2024. it was mutually agreed upon by the Board and the CEO Ihal a review of the Board is necessary. This process is currently in progress. overseen by a designated Trustee, the CEO, the head of Clinical, and the.current Chair. Professor Adam Fox. The review in 2024 will assess the existing members of Ihe Board, aiming to updale its Terms of Reference and identify any knowledge gaps that may necessitate recwilmenl. It is important to note that the Board viill not receive any financial remuneration. I would like to express my gratitude to all members ol the Health Advisory Board for their invaluable Support to Allergy UK. l. Presldenl and Vlce-Presldent Professor P. Howarth. our esteemed PreS￿ent, is a founding member ol our Charily. He served as a Professor of Allergy and Respiratory Medicine and held the position of Honorary Consultant Physician in Medicine at the Universily of Soulhamplon. Renowned internationally. he has dedicaled his career to advocating for the allergic community, including his previous roles as a Trustee and Ambassador for Allergy UK. We extend our.heartfelt gralitude for his unwavering support over the pasl thirty years. Professor Howarth has now stepped down from his posilion, and Allergy UK is actively seeking a new presidenl. Page 14

The British Allergy Foundatlon IA company Ilmited by guarantee) Trusteès. report (contlnued) For the year ended 31 March 2024 Plans for future perlods In 2024125 we will continue lo adhere lo the organisalions current objectives bul also plan for our new2025- 2030 strategy. Our focus for Ihe next 12 months Include.. Oevelopmenl of the 2025-2030 Stralegy Conlinued monitoring of the economic situation and Ihe eflect this has on the Charity's incoine streams and olher aclivilies Empowerment of the voice of the allergic community Ihrough advocacy and our'll's time lo lake allergy serioiisly, campaign and other public relations aclivilies across the UK Expanding ou supporter bases and ensuring we promole piogrammes that have a significant impact on the qualily of life ol the allergic comniunily Broadening the work that we are doing with UK companies, as we continue lo diversify our inc0177e generation activities Ihrough fundraising and oiir trading subsldiary activities Exploring new and innovalive revenue-generaling opportunities Continue to develop our youth engagement programmes Statement ol Tru8lees' re$pon8lbllltlo8 The Trustees (who are also the directors of the Charity for the purposes of company law) are responsible lor preparing the Trustees, report and the financial slatemenls in accordance with applicable law and United Kingdom Accounting Standards {Uniled Kingdom Generally Accepted Accounting Practice). Company law requires the Trustees to prepare financial slatements for each financial . Under company law, the Trustees musl not approve the financial statements unless they are satisfied that they give a true and fair view of the stale ol affairs of the Group and the Charity and of their incoming resources 2nd application of resources, including their income and expenditure, for that period. In preparing these financial stalernent8, the Trustees are required to.. select suilable accounting policies and then apply them consislenlly; observe Ihe methods and principles of the Charities SORP (FRS 102).. make judgemenls and aGGounling estimates that are reasonable and prudent., Slate whether applicable UK Accounling Standards (FRS 102) have been followed, subject to any material , departures disclosed and explained in the financial stalemenls; prepare the financial stalemenls on the going concem basis unless it is inappropriate to presume Ihal the Group will continue in business. The Twstees are responsible for kéeping adequate accounling records Ihal are sufficient to show and explain the Group and Ihe Charrty's transactions and disclose with reasonable accuracy at any time the financial position of the Group and the Charily and enable them to ensure that the financial statements comply with the Companies Acl 2006. They are also responsible lor safeguarding the assets of the Group and Ihe Charily and hence for taking reasonable steps for the prevèntion and detection of fravd and other irre9ularities. Dlsclosure of information to auditors Each of the persons who are Trustees at the time when this Truslees. report is approved has confirmed that.. so fai as Ihat Trustee is aware, there is no relevant audit information ol which the charitable group's auditors are unaware. and that Trustee has taken all the steps that ought to have been taken as a Trustee in order lo be aware of any relevant audit information and to establish that the charitable group's auditors are aware of that information. "Page 15

The British Allergy Foundation (A company limited by guarantee) Trustees. report (continued) For the year ended 31 March 2024 Auditors The auditors, Kreston Reeves LLP, have indicated their willingness lo continue in office. The designated Twslees will propose a moliori reappoinling the auditors at a meeling of Ihe Trustees. Approved by order of the members of the board of Trustees and signed on their behalf by.. Mr P Frampton Chair Date: £ i/lI/LJ'lQ Page 16

The Brilish Allergy Foundatlon (A company Ilmlted by guarantee) Ind•p•ndent auditors, raport to the Members of The British Allergy Foundation Oplnlon We have audited the financial statemenls of The British Allergy Foundation (the 'parent charitsble companl) and its subsidiaries (the 'group') for the year ended 31 March 2024 which comprise the Consolidated statement of financial activities, the Consolidated balance sheet, th8 Charity balance sheet. the Consolidated statement of cash flows and the related notes. including a summary of significant accounting policies. The financial reporting framework that has been applied In their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland, (United Kingdom Generally Accepted Accounting Practice). In our oplnion the financial statements- give a Irue and fair view of the state of the Group's and of the parent charitable companys affairs as at 31 March 2024 and of the Group's incoming resources and application of resources, including its Income and expenditure for the year then ended; have been properly.prepared in accordance wlth United Klngdom Generally Accepted Accounting Practice., and have been prepared in accordance wilh the requlrements of the Companies Act 2006, Charitles Act 2011, the Charities and Trustee Investment (Scotland) Act 2005 and regulations 6 and 8 of the Charilies Accounts (Scotland) Regulations 2006. 8as18 for oplnlon We conducted our audit In accordance wbth Intemational Standards on Auditing (UK) (ISAS (UK)) and appllcable law. Our responsibilltles under those standards are further described in the Auditors, responsibilities for the audit of the financial statements section of our report. We are independent of the Group in accordance with the ethical requirements that are relevant to our audit of the !Inancial statements in the United Kingdom, including the Financial Reporting Council's Ethical Standard. and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion. Con¢luslons relating to golng ¢onc•rn In auditing the financial statements, we have concluded that the Truslees, use of the going concern basis of accounting in the preparation of the financial statements is appropriate. Based on the work we have performed, we have not identified any material uncertalnlies relating to evenls or conditions that, individually or collectively, may cast significant doubt on the Group.'s or Ihe parent charitable companls ability to continue as a going concern for a period of at leasl twelve months from when the financial statements are authorised for issue. Our responsibilities and the responsibilities of the Trustees with respect to going concern are descrlbed in Ihe relevant sections of Ihis report. Page 17

The Brllish Allergy Foundation (A company limlted by guaranteè) Independent auditors. report to the Members of The Brbtish Allergy Foundatlon (contlnued) Other Inforniation The other information comprises the information in'cluded in the Annual report other than the financial statements and our Auditors, report thereon. The Trustees are responsible for the other infomiation contained within the Annual report. Our oplnlon on the financial statements does not cover the oth'er Information and, except to the extent othepwise explicitly stated in our report, we do not express any forrn of assurance conclusion thereon. Our responsibility is to read the other information and, in doing so. consider whether the other infonnation is materially inconsistent with Ihe financial statements or our knowledge 'obtained in the course of the audil. or otheThvise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstalements, we are required to detennine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material mlsstatement of this other Informatlon, we ar8 required to report that fact. We have nothing to report in this regard. Oplnlon on other matt•rs pr•scrlb•d by Ihe Companles Act 2006 In our opinion, based on the work undertaken in the course of the audlt: the information given in the Trustees, report for the financial year for which the financial statements are prepared is consistent with the financial statements. the Trustees, report has been prepared in accordance wilh applicable legal requirements. Mattern on whlch we are requlrod to r•port by •xc•ptlon In the Ilght of our knowledge and understanding of the charitable company and its envlronment obtalned In the course of the audit, we have not identified material rnisstatements in the Trustees, report. We have nothing to report in respect of the following matters in relation tv which Companies Act 2006 and the Charities Accounts (Scotland) Regulatlons 2006 (as amended) require us to report to you rf, in our opinion: the parent'charltable company has not kept adequate and sufficient accounting records, or retums adequale for our audbl have not been received from branches not visited by us; or the parent charitable company financial statements are rK)t in agreement with the aC￿)Unting records and returns., or certain disclosures of TfUStees' remuneration sp,ecified by law are not made; or we have not received all the informatlon and explanations we requlre for our audll. or the Trustees were not entitled to prepare the financial statements in accordance with the small companies regime and take advantage of the small companies, exemptions in preparing the Trustees, report and from the requirem8nt to prepare a Strategic report. Responslbllltles of trustees As explained more fully in the Trustees, responsibililies statement, the Truslees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial ststements and for being satisfied that they give a true and fair view. and for such intemal control as the Trustees determine is necessary to enable the preparation of financial statements thal are free from material misstatement. wheiher due to fraud or error. In preparing the financial statements, the Trustees are responsible for assessing the Group's and the parent charitable company's ability to continue as a going concern. disclosing. as applicable, matters related lo going concem and using the going concem basis of accounting unless the Twstees either intend to liquidate.the Group or the parent charitable company or to cease operations. or have no realistic altemative but to do so. Page 18

The Britlsh Allergy Foundalion (A company limited by guarantee) Independ•nt auditors. report to th• Mambers of Tho Brltlsh Allergy Foundatlon (conllnued) Audltors. responslbllitl•s for the audlt of the flnancial statements We have been appointed as auditor under section 44{1)(c) of the. Charities and Trustee Investment (Scolland) Act 2005 and under the Companies Act 2006 and report in accordance with the Act and relevant regulations made or having effect thèreunder. Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement. whether due to fraud or error, and to issue an Auditors. report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAS (UK}'will always detect a material misstatement when it exists. Misstatements Can arise from fraud or error and are considered material if, individu811y or in the aggregate, they could reasonab'ly be expected to influence the economic d8clsions of users taken on the basls of these financial ststements. Irregularities. including fraud,. are instances of non-compliance with lav￿ and regulations, We design procedures in line with our responsibilities, outlined above. to detect material misstatements in respecl of irregularilies, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below: Capability of the audit in detecting Irregulan'lies, includlng fraud Based on our understanding of the charity and the sector as a whole, and through discussion with Ihe Trusiees and other rnanagement (as required by auditing standards). we identified that the principal risks of non- compliance with laws and regulalions related to health and safety and employment law. We considered the extent to which non-compllance might have a material effect on the financial statements. We also considered those laws and regulations that have a direct impact on the p￿paratIon of the financial statements such as the Charities SORP (FRS 102) Second Edition (released October 2019), the Companies Act 2006. taxation and pension legislation. We comrnunicated identified laws and regulations throughout our learn and remained alert to any indications of non-compliance throughout the audit. We evaluated management's incentives and opportunities for fraudulent manipulation of the financial statements (including the risk of override of controls), and detemined Ihal the principal risks were related to incorrecl recognition of legacy income, posting inappropriale journal entrles and management bias in accountlng estimales and ludgementsl areas of Ihe financial stalements. Audit procedures performed by the engagemenl team included: Discussions with managernènt and assessrnent of krM)wn or suspected instances of non-compliance with laws and regulations (including health and safety) and fraud; and Assessment of identffied fraud risk factors; and Review of expenditure to confirm no evidence of personal berieflt; and Identif￿ng and assessing the design effectiveness of controls that management has in place to prevent and detect fraud. and Challenging assumptions and.judgements made by rnanagement in its significant accounting estimates; and Perfomiing analytical procedures to identify any unusual or unexpected relationships, including relaled party transactions. that may indicate risks of material misstatement due to fraud; and Confimation of related parties with management. and review of transactions Ihroughout the period to identify any previously undisclosed transactions with related parties outside the normal course of business. and Reading minutes of meetings of those charged with govemance,. and Review of significant and unusual transactions and evaluation of the underlying financial rationale sUppO￿.ng the transactions. and Identifying and testing joumal entries, in particular any manual entries made at the year end for financlal statement preparation. Page 19

The British Allergy Foundatlon (A company Ilmlted by guarantee) Independent auditors. report to the Members of The Britlsh Allergy Foundation (continu•d) Because of the inherent limitations of an audit,. there is a risk thal we will not detect all irregularities, including those leading to a material misstatement in the financial statements or non-compliance with regulation. This risk increases the rnore that compliance with a law or regulation is removed from the events and transactions reflected in the financial statements, as we will be less likely to become aware of instances of non-compliance. The risk is also greater regarding irregularities occurring due to fraud rather than effor. as fraud involves intentional concealment. forgery. collusion. omission or misrep.resentation. As part of an audit in accordance with ISAS (UK), we exercise professional judgement and maintain professional sceptiCi8m throughout the audlt. We also., Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficienl and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of iDlemal control. Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate In the circumstances, but not for the purpose of expressing an opinion of the effectiveness of the charitable companys internal conlrol. Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Trustees. Conclude on the appropriateness of the Trustees, use'of the going concern basis of accounting and,. based on the audit evidence obtained, whether a material uncertainly exists relaled to events or conditions that may cast significant doubt on the charitable companvs ability to continue as a. going concern. If we conclude that a malerial uncertainty exists, we are required to draw attention in our Auditors, report to the related disclosures in the financlal stalements or, if such disclosures are inadequate, to modlfy our opinion. Our conclusions are based on the audrt evidence obtained up.lo the date of our Auditors, report. However. future events or conditions may cause the charitable company to cease lo continue as a going concem. Evaluate the overall presentation. structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achleves falr presentatlon. Obtain sufficient appropriate audil evidence regardlng the financial infornatlon of the entlties or buslness activitl8S Wlthln the Group to express an opinion on the consolidated flnancial statements. We are responsiblé for the direction, supervislon and performance of Ihe Group audit. We remaln solely responsible for our audit opinion. We communicate with those charged with governance regarding, among other matters. the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audlt, Page 20

The Britlsh Allergy Foundatlon (A company limlted by guarantee) Independent auditors. report to the M•mbers of The British Allergy Foundation (¢ontinued) Use of our report This report is made solely to the charitable companrfs trustees, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006, and to the charitable companls irustees, as a body. Part 4 of the Charities {Accounts and Reports) Regulations 2008 and regulation 10 of the Charities Accounts (Scotland) Regulations 2006. Our audit work has been undertaken so that we might state to the charitable companys trustees those matters we are required to state to them in an Auditors, report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone olher than the charitable company and its members. as a body, for our audit work. for thls report. or for the opinions V￿ have formed. Samantha Rouse FCCA DChA (S•nlor statuiory audltor) for and on behalf of Kr•slon Reeves LLP Chartered Accountants Statutory Auditor Canterbury Date: 22 November 2024 Kreston Reeves LLP are eligible to act as auditors in terms of section 1212 of the Companies Act 2006. Page 21

The Brltlsh Allergy Foundatlon IA company Ilmlted by guarantee) Consoltdated Statement of financlal acllvilles (Incorporallng Income and expendllure account) For the year ended 31 March 2024 Unreslrlcted lunds 2024 Restilcted funds 2024 Total funds 2024 Total funds 2023 Note Income from: Donations and legacies Charitable activities Olher trading activities Investments Other income 51,843 27,764 1.136,222 19,143 113,688 61,643 103,486 27,764 1,136,222 19,143 113.688 158.523 22,410 1,338,224 5,691 Total Income 1,348.660 51.643 1,400,303 1,524.848 Expendlture on.. Raising funds Charitable activities 206,523 1,102,991 206,S23 1,198,174 286,972 1.386.245 95.183 Total oxpendituro 1,309,S14 95.183 1,404,697 1,673,217 Not movement In funds 39.146 (43,540) 14,394) (148,369) Reconclllatlon of funds: Tolal funds brought lorward Net movement in funds 861,273 39,146 106,057 (43.640) 967,330 14,394) 1.115,699 (148,369} Total funds carrled forward 900,419 62,517 962,936 967,330 The Consolidated slalemenl of financlal aclivilies Includes all gains and losses recognised in the year. The notes on poges 28 to $4 form part of Ihese financial Slatemenls, Page 22

The British Allergy Foundation (A company limited by guaranteel Registered number: 04509293 Consolldated balance sheet As at 31 March 2024 2024 2023 Note Flxed assets Intangible assets Tangible assets Investments 14 15 16 61.947 17,260 14 92,521 17,227 14 79,221 109,762 Current assets. Stocks Debtors Investmenls .Cash at bank and In hand 17 18 19 2.252 299,667 200,000 667,900 961 294,920 482.249 520,896 1.169.719 1,279,026 Creditors.. amounts falling due wrthin one yeat 20 1286,0041 {421,458) Net current agsetg 883,715 857,568 Tolal nèt assets 962,936 967,330 Chailly funds ReslTicted funds ljnreslricled funds 21 21 62,S17 900,419 106,057 861,273 Total funds 962,936 967,330 Page 23

The Brltlsh Allergy Foundatlon (A company Ilmlted by guarantee) Reglslered number: 04509293 Consolldated balance sheel l¢ontlnued) A5 at 31 March 2024 The Trusteés acknowledge their responsibilities for complying wilh the requiTemenls of Ihe Act wilh respecl lo accounting records and preparation ol financial sla18menls. The financial slalemenls have bean prepared In 8ccordance with the provisions appliGable lo entilles subject lo the small companies regime. The financlal statements were approved and aulhorlseLI lor Issue by the Trustees and signed on th6ir behalf by:. Mr P Frampton Chalr Dat6.. ii/ii /loZ4 The notes on pages 28 10 54 form part of Ihese financlal staleinenls, Page 24

The Brltlsh Allergy Foundallon (A Company limlted by guarantee) Reglstered number: 04509293 Charlty balance sheet As at 31 March 2024 2024 2023 Note Flxed assets Ihlangible assets Tangible assets Investments 14 15 16 61.947 17,118 16 92,521 17.037 16 79,081 109,574 Current assets Slocks Deblors Inveslmenls Cash al bank and in hand 17 18 19 2.252 79,976 200.000 638.521 206,701 462,249 260,287 920,749 930.198 Creditors: amounts falllng due wilhln one year 20 158,075) (93.623) Net current asset8 862,674 836.575 Total nel a88elS 941,755 946.149 Charlty fund8 Restricted funds Unrestricted funds 21 21 62,51Y 879,238 106,057 840,092 Total funds 941,755 946,149 The Charily's nei movement in funds for Ihe year was. £6,969 (2023 - £{128,681)). . Page 25

The Britlsh Allergy Foundation (A company Ilmlted by guarantee) Registered number: 04509293 Charlty balance sheet (contlnuedl As at 31 March 2024 The Tiuslees acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and preparation of fi'nancial statements. The financial statements have been prepared in accordance with the provisions applicable to entities subject to the small companies regime. The financial statements were approved and aulhorised lor issue by the Truslees and signed on their behalf by.. Mr P Frampton Chair Dale.. z l/ii/z v29 The notes on pages 28 to 54 fomi part ol these financial si8lement8. Page 26

The 8rilish Allergy Foundatlon (A company limited by guarantee) Consolidated statement of cash flows For the year ended 31 March 2024 2024 2023 Note Cash flows from operatlng actlvities Net cash (used in)Iprovided by operaling activilies 24 (115,024) (327,071) Cash flows from Invesllng actlvltles Inlerest received Purchase of intangible assels Purchase of tangible fixed assets Decreasel(increase) in short tem deposit accounls 19,143 (2,700) (16,664) 262,249 5.691 (550} (1,201) (2.249) Net cash provlded by Investlng actlvitles 262,028 1,691 Change in cash and cash equlvalenls In the year Cash and cash equivalents at the beginning of the year 147,004 (325,380) 846,276 520,896 Cash and ¢ash equlvalents at Ihe end of the year 25 667.900 520,896 The notes on pages 28 lo 54 lorm parl of these financial stalemenls Page 27

The 8rltlsh Allergy Foundation IA company Ilmlled by guarantee) Notes to the flnancial statements For the year ended 31 March 2024 General informatlon The British Allergy Foundation is a charilable private company limrted by guarantee, Incorporated in England, Wales and Scotland. The liability of each member In Ihe event of a winding up is limited to £1. The registered offi'ce is London House Business Centre, .Thames Road. Craylord, Darlford, England, DA1 4SL. The principal aclivily of the Charity is to incfease awareness of al￿rgY'and causes of anaphylaxis Ihrough seTvices, advocacy. campaigns for policy and legislation changes. education on management and prevention ol allergy. supporting Ihe allergic community, promoting research into causes of allergy and improving quality of life, advocacy, advice. support and information services. Accountlng pollcle8 2.1 Basls of pr•paratlon of flnanclal statements The financial Statements have been prepared in accordance wrth the Charities SORP {FRS 102> - Accounting and Reporting by Charities.. Statement of Recommended Practice applicable lo charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019), the Financial Reportin9 Standard applicable in the UK and Republic of Ireland (FRS 1021 and the Companies Act 2006. The British Allergy Foundation meets the definition of a public benelil entity under FRS 102. Assets and liabilities are initially recognised al hislorical cosl or transaction value unless otheThvise staled in the relevant accounting policy. The Consolidated slalemenl ol financial activilies (SOFA) and Consolidated balance sheet consolidate the financial slatements of Ihe Charity and ils subsidiary undertaking. The resulls of the subsidiary are consolidated on a line by line basis. The Charity has laken advantage of the exemption allowed under section 408 of the Cornpanies Act 2006 and has not p￿sented ils own Statement of financial activities in these financial stalements. Page 28

The Brltlsh Allergy Foundallon (A company Ilmlted by guarant••) Notes to Ihe financial statements For the year ended 31 March 2024 Accounting policies (continued) 2.2 Income All income is recognised once the Charity has entitlement to the income, after any performance conditions have been mel, it is probable Ihal the income will be received and the amount of income receivable can be measured reliably. Incoming Tesources from charilable trading activllie8 are recognised as follows.. The sale of goods - revenue is recognised when donated goods are sold.. The renderin9 of services - revenue is recognised as follows.. Applications for Ihe seal of approval when the application has been signed and the terms agreed., Renewal of Ihe seal of approval in the month of commencement of the new period: and SeNices. such as training. in the month the services are supplied. Voluntsry income is feceived by way of grants, donaiion$. legacies and gifts and 1$ included in full in the Statement of Financial Activilies when receivable. Grants, where enlillement is not conditional on the delivery of a specific performance by the charity, are recognised when the charity becomes unconditionally entitled to the granl. Incoming resources from granls, where related to performance and specific deliverables, are accounted for as the charity earns the right lo consideration by its performance. Investment income is included when fecefvable, Legacies are included when the Charity has legal entitlemenl. the amount can be measured reliably and il is probable Ihat Ihe income will be received. Income tax recoverable in relation to investment income is recoghised 81 the tirne the investment incorne is receivable. 2.3 Expenditure Resources expended are included In the Statement of Financial Activities on an accrual basis and have been classified under headings that aggregate all costs related lo the catggory inclusive ol any VAT which cannot be recovered. Expenditure is recognised where there is a legal or conslruclive obligalion to make payment lo a third party, it is probable that seltlemenl will be required and Ihe amount of the obl￿atIon can be measured reliably. Fundraising costs are those incurred in seeking voluntary contributions and Ihe staging of fundraising evenls. Support costs Support costs are those costs incurred direclly in support ol expenditure on the objects of Ihe company. Allocatlon to support costs Certain expendilure is directly attriculable lo specific activities and has been included in Ihose cost categories. Certain other costs, which are atlribulable lo more Ihan one activity. are apportioned across cost calegorbes on Ihe basis of an estimate of Ihe proportion of lime spent by staff on those aclivilies. Page 29

The Brltlsh Allergy Foundatlon (A company Ilmlted by guarantee) Notes to the financial statements For the year ended 31 March 2024 A¢¢ountlng pollcles {conllnued) 2.4 Goveinment grants Income from govemment grants is included at the point of application for the funds if that funding is considered to meet the criteria of measurability, reliabi&'ty and probability. OtheNiise it is accounted for upon receipt. 2.6 Forelgn currencles Monelary assets and liabilities denominated in foreign currencles are translaled into sterlin9 at rales of exchange ruling at the reporting dale. Transactions in foreign currencies are Iranslated into sterling at the iale ruling on the date of the transaction. Exchange gains and losses are recognised in the Consolidated statemenl of financial activities. 2.6 Intanglble assets and amortlsatlon Intangible assets costing £1.000 or more are capitalised and recognised wthen future economic benefits ale probable and the cosl or value of the asset can be measuied reliably. Intangible assets are initially recognised at cost. After recognition, under the cosl model, intangible assels are measured al cosl less any accumulated amortisation and any accumulated impairment losses. Amortisalion is provided on intangible asséls al rale8 cakulated lo wriie off the cosl of each asset on slraight-line basis over ils expected useful life. Amortisalion is provided on the lollowing bases., Website CRM Development costs 10 ./• slrai9hl line 10 0/0 Straight line 2.7 ,Tanglble flxed assets and depreciatlon Tangible fixed assets costing £500 or more are caprtalised and recognised when future economic benefits are probable and the cost or value of Ihe asset can be measured reliably. Tangible fixed assets are initially recognised al cost. After recognition, under the cost model. tangible fixed assets are measured at cost less accumulated depreciation and any accumulated impairment losses. All costs incuried to bring a tangible fixed asset into ils inlended Working condition should be included in Ihe measurement of cost. Deprecialion is charged so as to allocate the cost of langible fixed assets less Iheir residual value over their estimated useful lives, on a reducing balance basis. All new fixed assets purchased in 2022123 and subsequently are depreciated on a straight-line basis. Depreciation is provided on the following basis.. Furniture and fittings. Compuler & office equipment 250/0 reducing balance 25•/0 reducing balance Page 30

The Brltlsh Allergy Foundatlon IA company limlted by guarantee) Notes to the flnanclal statements For the year ended 31 March 2024 Accountlng pollcles (contlnued). 2.8 Invesiments Fixed ass8t investments are a form of financial instrument and are initially recognised at theii transaction cosl and subsequently measured al fair value at the Balance sheet dale, unless the value cannot be measured reliably in which case it is measured at cost less impairment. Investment gains and.losses, whether realised or unrealised, are combined and presented as 'Gainsl{Losses) on investments, in the Consolidated statement of financial activities. Investments in subsidiaries are valued at cost less provision for impairment. 2.9 Slocks Slocks are valued at the lower of cost and nel realisable value, being the estimated selling price less costs lo complete and sell. Cost is based on the cost of purchase on a firsl in, first out basis. Work in progress and finished goods include labour and attribulable oveiheads, At each balance sheet date, stocks are assessed for impairment, If stock is impaired. the carrying amounl is reduced to its selling price less costs lo complete and sell, The impairment loss is recognised immediately in profil or loss. 2.10 Debtors Trade and other debtors are recognised at the settlement amount after any trade discount offered. Prepayments are valued al Ihe amount prep8id net of any trade discounts due. 2.11 Cash al bank and in hand Cash al bank and in hand includes cash and short-lerm highly liquid investments with a short maturity of three monlhs or less from the dale of acquisition or opening of the deposil or similar account. 2.12 Liabllltles and provlsions Liabilities are recognised when there is an obligation at the Balance sheet dale as a resull of a past event, il is probable that a transfer of economic benefrt will be required in selllemenl, and the amount of the settlement can be estimated reliably. Liabilities are recognised at the amount that the Charity anticipates il will pay to settle the debt or Ihe amount il has received as advanced payments for the goods or services it must provide. Piovisions are measured al the best estimate of the amounls required to settle the obligation. Where the elfect of the time value of money is material, the provision is based on the present value of those amounts, discounted al the pre-tax discounl rate that reflects the risks specific to the liability. The unwinding of the discount is recognised in the Consolidated statement of financial aclivities as a finance cost. 2.13 Flnanclal Instruments The Group only has financial assets and financial liabilities of a kind thal qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured al Iheir seltlement value with the exception of bank loans which are subsequently measured at amortised cost using the effective interest method. Page 31

The British Allergy Foundation IA company Ilm5ted by guarantee) Notes to the financial statements For the year ended 31 March 2024 Accountlng pollcle8 (continued) 2.14 Operatlng leases Rentals paid under operaling leases are charged to the Consolidaled Slatement of Financial Aclivities on a straighl-line basis over the lease term. 2.15 Penslons The Group operales a defined conlribulion pension scheme and the pension charge represents the amounts payable by Ihe Group lo Ihe fund in respect of Ihe year. 2.16 Fund accountlng General funds are unrestricted funds whlch are available for use at the discretion of the Trustees in furtherance of the general objectives of the Group and which have not been desigTraled for other purposes. Designated funds comprise unrestricted funds Ihat have been set aside by the Trustees for particular purposes. The airn and use of each designated fund is set out in the notes to the financial statemenls, .Restricled funds are lunds which are to be used in accordance with specific restrictions imposed by donors or which have been raised by the Group for particular purposes. The costs of raising and administering such funds are charged againsl the specific fund. The aim and use of each restricted fund is sel out in Ihe notes to the financial slatements. Inveslment income. gains and losses are allocated to the appfopriate fund. Income from donatlons and legacles Unrestricted Restrlcted funds funds 2024 2024 Total funds 2024 Donations Legacies Grants 48,286 53 3.504 48,286 53 55.147 51,643 51.843 51,643 103,486 Unrestricted funds 2023 Reslricted funds 2023 Total funds 2023 Oonations Granls 36.265 36,265 122,258 122.258 36,265 122,258 158,523 Page 32

The Brltish Allergy Foundatlon (A company Ilmlted by guarante•) Notes lo the flnanclal statements For the year ended 31 March 2024 Income from charitable actlvllies Unrestricled funds 2024 Total funds 2024 .Tolal funds 2023 Sale ol translation cards Fees recelved 26.430 1,334 26,430 1,334 22.005 405 27,764 27,764 22,410 Income from other tradlng a¢iivlll¢s Income from fundralslng events Unrestrictéd funds 2024 Total funds 2024 Total funds 2023 Fundraising events 13.550 13,560 20.918 Income from trading subsldlary Unrestrlcled funds 2024 Total funds 2024 Total funds 2023 Seal of approval Renewals Allergy Friendly Products Corporate partneis Alerts Allergy Awareness Scheme 220,453 675.103 85,333 137,383 4.400 220,453 675,103 85,333 137,383 4,400 357.815 689,894 60,700 205,000 3.120 777 1.122,672 1,122,672 1.317.306 Page 33

Th• Britlsh Allergy Foundatlon (A company1Smlted by guarantee) Notes to the financlal statements For the year ended 31 March 2024 Investment Income Unrestricted funds 2024 Tolal funds 2024 Tolal funds 2023 Interest received 19,143 19,143 5,691 Other in¢omlng resources Unrostrlcted funds 2024 Tolal fund8 2024 Total funds 2023 Other income 113,688 113,688 Expendlture on ralslng funds Costs of ralslng voluntary Income Unrestflcled funds 20¥4 Total funds 2024 Total lunds 2023 Direct costs Professional fees 4.733 4,722 4.733 4,722 2,178 2,653 9.455 . 9,45S 4,831 Fundralslng tradlng exp•ns•$ UnrestrScted funds 2024 Total funds 2024 Fundraising expenses 16,558 16.558 Page 34

The Britlsh Allergy Foundation (A company limited by guarantee) Notes lo the flnanclal statements For the year ended 31 March 2024 Expendllure on ral8lng funds (contlnued) Fundralslng trading expenses (conllnued) Unrestricted funds 2023 Restricted funds 2023 Total funds 2023 Fundraising expenses 9.132 31.290 40,422 Expendlture on tradlng subsldlary Unrestrlcted funds 2024 Total fuhd$ 2024 Total funds 2023 Cost of sales 180,510 180,510 241,719 Analysls of expendlture on charllable actlvltlos Summary by fund type unrestrIct￿ Restricted funds funds 2024 2024 Total 2024 Charilable aclivities 1,102,991 95.183 1,198,174 Unrestricted funds 2023 Total 2023 Charilable activities 1.386,245 1,386,245 Page 35

The Brltlsh Allergy Foundatlon IA company limlted by guarantee) Notes to'the financial statements For the year ended 31 March 2024 10. Analysls of expendllure by actlvltles Activltles undertaken dlreclly 2024 Support costs 2024 Total funds 2024 Charitable activities 942,299 255,875 1.198,174 Activities undertaken direclty 2023 Support costs 2023 Total funds 2023 Charilable activities 1.024,622 381,823 1,386.245 Anatysls of dlr•ct cosi8 Total funds 2024 Tbtal funds 2023 Staff costs Communicallons Other direct costs 830,146 91,208 20,945 877.828 127,360 19,434 942,299 1,024,622 Page 36

The British Allergy Foundation IA company Ilmlted by guarantee) Notes to the flnanclal stalements For the year ended 31 March 2024 10. Analysls of expendlture by acllvities (contlnued Analysls of support CO8ls Total funds 2024 Total funds 2023 Premises Communications Legal & professional General office expens.es Depre¢ialion, 8mortlsation & impairment Financial charges Govemance costs 90.589 284 5.770 94.103 38,641 9,238 17,360 117.758 5.292 32.889 111.753 27.450 31.506 34,975 255,876 361,623 11. Audltor8' remunerallon The auditors, remuneration amounts to an auditor fee of £13,700 (2023 . £10.350), and remuneration in relation to the preparatlon ol the financial statements and corporation tax returns 01 £3.545 {2023 £4.125). 12. Staff costs Group 2024 Group 2023 Charlty 2024 Charity 2023 Wages and salaries Social security costs Contribution lo defined contribution pension schemes 740,962 69,231 783,375 74,217 740.962 69,231 783,375 74,217 19,953 2G,236 19,953 20.236 830.146 877.828 830,146 877.828 The average number of persons employed by the Charity during the year was as follows.. Group 2024 No. Group 2023 No. Charily 2024 No. Charity 2023 No, Headcount 23 22. 23 22 Page 37

Thft British Allergy Foundation (A company Ilmlted by guarantee) Noles to tho flnanclal statemenls For Ihe year ended 31 March 2024 12. Staff costs (continued) The average headcount expressed as full-time equivalents was". Group 2024 Group 2023 No. Charlty 2024 No. Charity 2023 No. Charitable activities Generating funds 19 19 19 19 22 22 22 22 The number of employees whose employee benefits (excluding employer'pension cosls) exceeded £60.000 was.. Group 2024 No. Group 2023 No. In the band £60.001- £70.000 In the band £70.001- £80,000 Page 38

The British Allergy Foundation (A company Ilmlted by guarantee) Noles to the financlal statements For the year ended 31 March 2024 13. Trustees, remuneratlon and expenses During the year, no Trustees received any remuneration or other benefits (2023 - £NIL}. During the year ended 31 March 2024, expenses totalling £4,690 were reimbursed or paid directly lo 6 Trustees (2023 - £2,823 to 5 Trustees). These related to travel and hotel costs to atlend Board meetings, 14. Intanglble assets Group Computer software Patents Total Cost At 1 April 2023 Additions 74,931 2,700 144,644 219,576 2,700 Al 31 March 2024 77,631 144,644 222,275 Amortlsatlon At 1 April 2023 Charge for the year Impairment charge 61,210 3,810 16,000 75,844 14,464 127,054 18,274 15,000 At 31 March 2024 70,020 90,308 160,328 Net book value Al 31 March 2024 7,,611 54,336 61,947 Al 31 March 2023 23,721 68,800 92,521 Page 39

The Brltlsh Allèrgy Foundatlon IA company limited by guaranteel Notes to the linancial stalements For the year ended 31 March 2024 14. Intanglble assets (continued) Charity Computer 80ftware Patent8 Total Cost At 1 April 2023 Additions 74.931 2.700 144,644 219.57.5 2.700 At 31 Mar¢h 2024 77,631 144,644 222,275. Amortlsallon At 1 April 2023 Charge for the year Impairment charge 61.210 3,810 16,000 75,844 14,464 127.061 18,274 15,000 At 31 March 2024 70,020 ' 9Q,308 160.328 Net book value At 31 March 2024 7.611 64,336 61,947 At 31 March 2023 23,721 68,800 92.521 Page 40

The Brltlsh Allergy Foundatlon (A company Ilmited by guarantee) . Notes to the flnanclal slatemenls For tho year ended 31 March 2024 1 S. Tangible lixed assets Group Computer & office equipment Furniture & fittings Total Cost or.valuation Al 1 April 2023 Additions Disposals 14,455 13,926 113.762) 53,S71 2,738 (17,583) 68,026 16,664 131.34S At 31 March 2024 14,619 38,726 53,345 Depreclatlon At 1 April 2023 Charge for the year On disposals 6,834 2,352 16,708) 43,965 2,915 113,273) 60.799 5,267 119,9811 At 31 March 2024 .2,478 33,607 36.085 Net book value At 31 March 2024 12,141 6.119 17.260 At 31 March 2023 7,821 9.806 17,227 Page41

The Brltlsh Allergy Fothndatlon IA company Ilmited by guarantee) Notes to the flnanclal statements For the year ended 31 March.2024 16. Tangible flxed assets Icontlnued) Charlty Compuler & office equipment Furniture & Total Cost or valualion At 1 April 2023 Additions Disposals 14,455 13,926 113,762) $0.908 2.738 (17,583) 65.363 16,664 131,345) At 31 March 2024 14,619 36,063 50,682 Depreclallon At 1 April 2023 Charge for the year On disposals 6,834 2,352 {6,708) 41.492 2,867 (13,273) 48,326 5,219 119.981) At 31 March 2024 2.478 31,086 33,664 Nat book value At 31 March 2024 12,141 4,977 17,118 At 31 March 2023 7,621 9,416 17.037 Page 42

The 8rltlsh Allergy Foundatlon IA company limlted by guarantee) Notes to the flnanclal statements For the year ended 31 March 2024 16. Flxed asset investments Investmants in subsidiary companies Group Cost or valuation Al 1 April 2023 14 At 31 March 2024 14 Investments In subsldlary companies Charlty Cost or valuaiion Al 1 April 2023 16 At 31 March 2024 16 Page 43

The British Allergy Foundatlon (A company limlled by guarantee) Notes to the flnancial slatements For the year ended 31 March 2024 16. Flxed. asset Investments Icontlnued) Prlnclpal subsldlarles The following were subsidiary undertakings of the Chartly.. Names Company Reglslered offlce or Class of Holdlng Included In number prlnclpal place ol bu81ne88 8hare8 consolldatlon Aller9y Research Ltd 035S0847 London House Business Cenlre. Thames Road, Craylord. Dartford, England, DA14SL 06302734 London House 8usines$ Cenlre, Thames Road. Crayford. Dartfoid. England, DA14SL 06300759 London House Buslness Cenlre, Thames Road, Crayford, Dartford, England, DA14SL Allergy England Ltd (Dorrnant) 08494679 London House Business Centie, Thames Road. Crayford. Darlford, England, DA14SL Allergy Scotland Ltd SC447980 272 Balh Street, Glasgow, Ordinary 100Yo No (Dormant) G2 4JR Allergy Europe Ltd (Dormant) 08695950 London House Business Cenlre, Thames Road, Crayford, Dartford, England, DA14SL Allergy Northern Ireland Ltd N1679729 58. Anlrim Enterprise {Qoimant) Agency. Unil 19 Greysione Road, Antrim, County Anlrim, Northern Ireland. BT411JZ Allergy Wales Ltd (Dormanl> 13459606 International Hou8e, 10 Chuichill Way. Cardiff, United Kingdom, CF10 2HE Ordinary 1 OOVO Yes Allergy UK Lld (Dormant) Ordlnary 100QA Y•5 Allergy Aware Scheme Ltd (Dormant) Ordinary 100°h Yas Ordinary 100Vo Yes Ordinary 100°/o Yes Ordinary 100% No Ordinary 1000h No The financial results of the subsidiaries for the year were., Names Incorne Expenditure Net assets Allergy Research Ltd Allergy UK Ltd (Dormant) Allergy Aware Scheme Ltd (Dofmanl) Allergy England Ltd {Dormant) Allergy Scotland Ltd (Dormant) Allergy Europe Ltd (Dormant) Allergy Northern Ireland Ltd (Dormant) Allergy Wales Ltd {Domiant) 1,123,773 (q,123,7731 21,183 Page 44

The British Allergy Foundallon IA company Ilmlted by guarantee) Noles to the flnanclal statements For the year ended 31 March 2024 17. Stocks Group 2024 Group 2023 Charlty 2024 Charily 2023 Goods for resale 2,252 961 2,252 961 Debtors Group 2024 Group 2023 Charlty 2024 Charity 2023 Du• wlthln one y•ar Trade debtors Amounts owed by group undertakings Other debtors Prepayments and accrued income 267,371 214,822 360 37,430 6,680 36,616 133,092 8.462 65.147 6,680 .36,616 14,951 65,147 299,667 294.920 79,976 206.701 19. Current asset Investmenls Group 2024 Group 2023 Charity 2024 Charity 2023 Short lerth deposits 200,000 462,249 200,000 462.249 Page 45

The Brfllsh Allergy Foundatlon ¢A company Ilmited by guarantee) ' Notes to the linanclal stalements For.the year ended 31 March 2024 20. Crfjdltors: Amounts falllng due wlthln one year Group 2024 Group 2023 Charity 2024 Charity 2023 Trade creditors Other taxation and social security Olher credilors Accruals and deferred income 30.409 23,1S2 1,677 230.766 78.215 19,016 1.988 322.239 10,353 21,387 1,677 24,658 44,615 19.016 1,988 28,004 286,004 421.458 58,075 93,623 Group. 2024 Group . 2023 Charlty 2024 Charity 2023 Deferred income at 1 April 2023 Resources deferred during the year Amounls released from previous periods 194.024 124,317 1194.024) 92,964 194.024 (92.964) 12,500 12,500 112.500) 18,024 12,500 (18,024) Def•rred Income al 31 March 2024 124,317 194,024 12,600 12.500 Page 46

The Brltish Allorgy Foundatlon (A company limited by guarantee) Notes to the financial statements Fof the year ended 31 March 2024 21. Slatement of funds Statement of lund$. ¢urrent year Balance at 31 March 2024 Balance at I April 2023 Transfers Inlout Income Expenditure Unrestrlcted funds Deslgnated funds Fixed Asset Fund Conlin9en¢y Fund Public Affairs Campalgn ReseNe Digital Media Reserve 17,037 466,220 16,219) 6,300 17,118 .466,220 16,395 6.455 16,395 6,455 606,107 (6,219> 5,300 506,188 Balance at 31 March 2024 Balance at 1 Aprll 2023 Transfers Inloul Incom• Expendllure General funds General Free Reserde Allergy Research Limited 333,985 21,181 1,348.660 11,304,296) IS.300) 373,050 21,181 355,166 1,348,660 11,304,295 {5,300 394,231 Total Unrestrlcted funds 861,273 1,348,660 (1,309.614) 900,419 Page 47

The British Allergy Foundation (A company limiled by guarantee) Notes to the flnanclal statements For the year ended 31 March 2024 21. Statement of funds {continued) Balance at 31 March 2024 Balance at 1 April 2023 Transfers inlout Income Expendlture Restrlcted funds HCP Scotland Training Fund Novartis Sanofi Youth Nutricia Pfizer Gorfield Weston IADPO 420 1.408 77.S83 4,680 9,466 12,600 {420) 1,.408 (77.583) {4,680) 24,186 24,186 9,466 26,000 2,457 26,000 2.457 (12,600 106,057 61,643 (96.183) 62,617 Total of funds 967,330 1,400.303 (1,404,697) 962,936 Page 48

The 8rltlsh Allergy Foundallon (A company Ilmlted by guarantee) Notes to the financlal statements For the year ended 31 March 2024 21. Statement of funds (continued) Statement of funds- prior year Balance at 31 March 2023 Balance at 1 April 2022 Transfers inlout Income Expenditure Unrestrl¢ted funds Deslgnated funds Awareness Campaign ReseDIe . Resource Building Reserve IT Reserve Fundraising ReseNe Flxed Assel Fund Conlingency Fund Project Delivery Reserye P.ublic Affair$ Campaign Reserve 5.120 100,291 10.000 42,562 26,720 466,220 75,000 (5,120) (100,291) (10,000) (42.562) (6.830) (2.853) 17.037 466.220 (75.OOOy 16,395 14.795 16,395 6.455 Digilal Media Reserve {8,340) 757,103 (248,143) (2,853) 506,107 Balance at 31 March 2023 Balance al 1 April 2022 Transfers inloul Income Expendilure General funds General Free Reserve Allergy Research Limrted 322,326 21,181 1,402.590. (1.393.784) 2,853 333,985 21.181 343,507 1.402,590 (1,393.784) 2,853 355,166 Total Unrestricted funds 1.100.610 1,402.590 (1,641.927) 861,273 Page 49

The 8rltlsh Allergy Foundatlon (A company limited by guarantee) Notes to the financial statements Fof the year ended 31 March 2024 21. Statement of funds (contlnued) Balance at 31 March 2023 Balance at 1 April 2022 Transfers inlout Income Expenditure Restrlcled funds HCP Scotland Training Fund Novartis Global Skin Sanofi Youth Nutricia Pfizer Aimmune Garfield Weslon 420 1,408 13,261 420 1,408 {13.261} 77,583 4,680 9,466 5.529 25,000 77,583 4,680 9,466 (5,529) (12,500) 12,500 15,089 122,258 (31,290) 106,057 Total of funds 1,115,699 1,524.848 {1.673.217) 967,330 The HCP (health care professlonal) Scotland Tralnlng Fund is to enable the charity to encouiage tiaining in allergy. by making grants to commilted HCPS to meet a percentage of their training cosls, 81 lime when the Health Service has Teduced theit funding in this area. Novartis provided grant lundin9 to create resources for people living wilh CSU in an e-booklet and a video. The resources aimed to provide an understandably informalion lo help them wilh their engagement with a GP. Global Skln provided grant funding for a Maslèrclass for healthcare professionals to manage skin allergy. S8nofl Youth is in relation lo the Development of Youth Engagement wilh Allergy. Nutricia provided sponsorship funding for the dielilian service Ihat offer. dielelic support for the under 5 yeaf olds. Garfield Weston is to help fund the operation of the Allergy helpline. Pfizer fund is for producing a booklet on skin to gkin. leaflet on Atpoi¢ Eczema and a leaflet on Eczma blood monitoring. Page 50

The British Allergy Foundation (A company Ilmlled by guarantee) Notes to the flnancial statements For the year ended 31 March 2024 22. Summary ol funds Summary of funds - current year Balance al 31 March 2024 Balance al I April 2023 Transfers Inloul Income Expendllure Designated funds General funds Restricted funds 506,107 355,166 106.067 15,219) 1,348,660 11,304.295) 61,643 (95,183) 5.300 {6.300) 506,188 394.231 62.517 967.330 1,400,303 (1,404,697) .962,936 Summary of funds- prlor year Balance al 31 March 2023 Balance at 1 April 2022 Transfers inloul Income Expendituie Designated funds General funds Restricted funds 757.103 343.507 15,089 (248.143) 1,402,590 (1,393,784) 122.258 (31,290) (2.853) 2,853 506,107 355,166 106,057 1.115.699 1,524,848 (1,673.217) 967,330 Page 51

The British Allergy Foundation (A company limited by guaranteel Notes to Ihe flnan¢lal'stalements For the year ended 31 March 2024 23. Analysis ol not assets between fund8 Analysis of net assèls belween funds . current perlod Unrestricted Restricted funds funds 2024 2024 Total funds 2024 Tangible fixed assets Intangible fixed assets Fixed asset investments Current asseis Credrtors due wlthln one year 17.260 61.947 14 1,107,203 (286,005) 17.260 61,947 14 1,169,720 1286,005) 62,517. Total 900,419 62,S17 962,936 Analysis of net assets between lunds - prlor perlod Unrestricted funds 2023 Restricted funds 2023 Total funds 2023 Tangible fixed assets Intangible fixed assels Fixed asset investments Current assets Credrtors due within one year 17,227 92,521 14 1,172,969 (421,458) 17,227 92,521. 106.057 1,279,026 {421,458) Total 861,273 106.057 967,330 Page 52

The Brltlsh Allergy Foundatlon (A company limlted by guarantee) Notes to the financial statements For the year ended 31 March 2024 24. Reconclllatlon of net movement In lunds to net cash flow from operatlng activltles Group 2024 Group 2023 Net expenditure for the period (as per Stalemenl of Financial Activities) 14,394) (148,369) Adjustmonls for: Depreciation charges Amortisalion charges Interest received Profit on disposal of intangibles (Profit)I loss on disposal of fixed assets Increase in slocks Decreasel(increase) in deblors Decrease in creditors Impairment charges 5,267 18.274 119,143) 6,989 21,039 (5.691) 17,507 11.363 4.416 <1.2911 [phone] 93,334 (85.163) (318,096) 15.000 Net cash used In operatlng actlvltles 1115.0241 (327,071) 26. Analysls of cash and cash equlvalenis Group 2024 Group 2023 Cash in hand 667,900 520.896 Total cash and eash equlvalents 667,900 520,896 26. Analysis of changes In net debt At 1 Aprll 2023 Cash flows At 31 March 2024 Cash at bank and in hand Liquid investments 520,896 462.249 147,004 (262,249 667,900 200,000 983,14S (115,245) 867,900 Page 53

The British Allergy Foundatlon (A company limited by guarantee) Notes to Ihe flnancial statements For the year ended 31 March 2024 27. Ponslon commitmenls The Group operales a defined contribution pension s¢h8me lor its employees.. The pension cost charge for the period represenls contributions payable by the Charity to the scheme and amounted to £19,953 (2023 - £20,236). At the balance sheet dale £Nil was recognised as a liabilily owed to the scheme (2023- £Nil). 28. Operatlng lease commltm•nls At 31 March 2024 the Group and the Charity had commitme'nts lo make future minimum lease payments under non-cancellable operating leases as follows.. Group 2024 Group 2023 .Charlty 2024 Charity 2023 Not laler than 1 year Later than 1 year and not later than 5 years 69,485 219,544 92.427 17,824 69,485 219,544 92,427 17,824 289,029 110,251 289,029 110,251 29. Related party transac'tions The charity has not entered into any related party Iransaclion during the year (2023,, £Nil), nor are there any outstanding balances owing between ielated parties and the Charily at 31 Mar¢h 2024 (2023.. £Nil). 30. Conlrolllng party There is no ultimate conlrolling parly. Page 54